ACTC to Enroll Patients With Better Vision in Stem Cell Trials
February 5, 2013
In late January, Advanced Cell Technology, Inc. (OTCBB: ACTC) announced that it is amending the patient treatment protocol to enroll patients with better vision for the remainder of its Phase I clinical stem cell trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) currently being conducted in the U.S. and Europe. As such, patients with a visual acuity of 20/100 will be eligible for enrollment in the remainder of the trials (whereas previously, only patients with a visual acuity of 20/400 were eligible to participate).
By treating patients at an earlier stage of SMD and dry AMD disease, ACTC believes that treatment can have a more significant positive impact on patients’ photoreceptor rescue and visual function.
Click here to read the full press release.
Jump down to form below to submit your own comments